Hematology

Top news of the week from Specialty Pharmacy Times.

Elotuzumab (Empliciti) with pomalidomide and dexamethasone (Pd) is the first triplet combination to be approved based on a randomized clinical trial using Pd as a comparator.

Officials with the FDA have approved elotuzumab (Empliciti) injection for intravenous use in combination with pomalidomide and dexamethasone for the treatment of certain patients with relapsed or refractory multiple myeloma.

A look at last week's top stories in the world of pharmacy.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.

Latest approval for carfilzomib offers a more convenient dosing option for patients with multiple myeloma.

Study establishes increased risk of all-site cancer for both men and women with diabetes, but the excess risk of cancer is greater for women.

New research identified predictors of long-term survival and health-related quality of life in patients with newly diagnosed multiple myeloma.

Currently, many patients experience a more than 3-month delay until their diagnosis is confirmed.

Elotuzumab with pomalidomide and low-dose dexamethasone met its primary endpoint in showing a statistically significant, clinically meaningful improvement in progression-free survival in patients with relapsed/refractory multiple myeloma.

Ibrutinib plus obintuzumab improved progression-free survival in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

From 1990 to 2016, incident cases and deaths from multiple myeloma have grown substantially.

There are 40 genes involved in the development of multiple myeloma, according to new research.

Officials with the FDA have expanded the approval of Amgen's blinatumomab (Blincyto) to include the treatment of adults and children with B-cell precursor acute lymphoblastic leukemia who are in remission but still have minimal residual disease.

Blinatumomab (Blincyto) can be used in patients with acute lymphoblastic leukemia who are in remission but still have minimal residual disease.

AbbVie and the International Myeloma Foundation will explore the outcomes of patients with multiple myeloma who have a specific genetic mutation.

Nilotinib (Tasigna) was previously granted priority review for the treatment of pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia.

Duvelisib monotherapy demonstrated safety and efficacy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Study results show patients with newly diagnosed multiple myeloma showed a lower risk of disease progression or death with daratumumab added to the standard regimen of bortezomib, melphalan and prednisone, than patients who were treated without daratumumab in their drug combination.

High-grade cardiovascular adverse events are twice as common when patients with multiple myeloma are treated with carfilzomib.

FDA grants priority approval to arsenic trioxide (Trisenox) plus tretinoin for leukemia treatment.

Denosumab (Xgeva) demonstrated non-inferiority to zoledronic acid in patients with multiple myeloma.

Daratumumab combination therapy tripled the minimal residual disease negativity rate among patients with multiple myeloma.

Nilotinib (Tasigna) label includes information for patients with chronic myeloid leukemia who may stop treatment after achieving remission.

CAR T cell therapy resulted in a high response rate among previously-treated patients with multiple myeloma.

The FDA previously found that PD-1/PD-L1 inhibitors may increase the mortality risk for patients with multiple myeloma.

The FDA granted approval to numerous specialty drugs last week.

Dasatinib (Sprycel) approved for pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia.

Nearly all patients treated with dasatinib (Sprycel) achieved a complete cyotgenic response.